Clinical trial

Effects of Berberine Ursodeoxycholate (HTD1801) Versus Dapagliflozin in Patients With Type 2 Diabetes Inadequately Controlled With Metformin

NCT06415773

Study summary

ClinicalTrials.gov

Effects of Berberine Ursodeoxycholate (HTD1801) Versus Dapagliflozin in Patients With Type 2 Diabetes Inadequately Controlled With Metformin

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE3

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention HTD1801 Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Dapagliflozin Normalized identity: dapagliflozin View linked drug · Find medicine records · Find other trials using this name

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2024-06-04

PhasePHASE3

Conditions

T2DM (Type 2 Diabetes Mellitus)unresolved

Interventions

HTD1801DRUG

DapagliflozinDRUG · verified · RxNorm: dapagliflozin

Sponsors & collaborators

Shenzhen HighTide Biopharmaceutical Ltd.lead sponsor

Mapped research locations

ChangshaChina4 LuoyangChina3 BeijingChina2 ShanghaiChina2 NanjingChina2 Xi'anChina2 ChangchunChina2 ShenyangChina2 NanchangChina2 XiangtanChina2 WuhanChina1 ChongqingChina1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06415773 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.